Aerovate Therapeutics Inc AVTE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $21.57
- Day Range
- $21.12–22.39
- 52-Week Range
- $9.41–32.42
- Bid/Ask
- $21.00 / $21.89
- Market Cap
- $606.02 Mil
- Volume/Avg
- 74,007 / 145,106
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.aerovatetx.com
Comparables
Valuation
|
Metric
|
AVTE
|
CBAY
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.52 | 12.65 | 1.98 |
Price/Sales | — | 111.01 | 2,253.05 |
Price/Cash Flow | — | — | — |
Price/Earnings
AVTE
CBAY
MORF
Financial Strength
|
Metric
|
AVTE
|
CBAY
|
MORF
|
|---|---|---|---|
Quick Ratio | 6.94 | 10.70 | 28.43 |
Current Ratio | 7.04 | 10.96 | 28.94 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
AVTE
CBAY
MORF
Profitability
|
Metric
|
AVTE
|
CBAY
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −48.35% | −30.06% | −18.85% |
Return on Equity (Normalized) | −53.58% | −51.97% | −19.43% |
Return on Invested Capital (Normalized) | −56.98% | −30.87% | −23.26% |
Return on Assets
AVTE
CBAY
MORF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sjjtvrmgd | Vhfh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zpxjdylv | Sqvwppf | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fydxhhzpd | Gpycv | $97.8 Bil | |
MRNA
| Moderna Inc | Jssczrsp | Kvtp | $41.3 Bil | |
ARGX
| argenx SE ADR | Cqymdmd | Mdljy | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Ydffqhtqm | Wgqvt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sxgygnnl | Dttmz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kghgqngj | Lwtgh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wrxgjckjgb | Mnjvkbp | $12.5 Bil | |
INCY
| Incyte Corp | Hsldpsr | Fnkmz | $11.6 Bil |